Orange Book product · Brand (NDA)
MOZOBIL
PLERIXAFOR
At a glance
Dec 15, 2008
Approved
Brand (NDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 15, 2008
17 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
PLERIXAFOR
Strength
24MG/1.2ML (20MG/ML)
Dosage form
SOLUTION
Route
SUBCUTANEOUS
TE code
AP
Application
NDA 022311
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2025PLERIXAFORGeneric (ANDA)
ANDA 217560 · HETERO LABS LTD VI
- 2024PLERIXAFORGeneric (ANDA)
ANDA 206644 · GLAND
- 2023PLERIXAFORGeneric (ANDA)
ANDA 208980 · ZYDUS PHARMS
- 2023PLERIXAFORGeneric (ANDA)
ANDA 215334 · AMNEAL
- 2023PLERIXAFORGeneric (ANDA)
ANDA 205182 · DR REDDYS
- 2023PLERIXAFORGeneric (ANDA)
ANDA 213672 · EUGIA PHARMA
- 2023PLERIXAFORGeneric (ANDA)
ANDA 215698 · MEITHEAL
- 2023PLERIXAFORGeneric (ANDA)
ANDA 211901 · MSN
- 2023PLERIXAFORGeneric (ANDA)
ANDA 205197 · TEVA PHARMS USA INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
